“Six Fewer Needles*!” — Peking University First Hospital Reports Breakthrough in Precision Prostate Biopsy, Published in The Lancet Sub-Journal

“Six Fewer Needles*!” — Peking University First Hospital Reports Breakthrough in Precision Prostate Biopsy, Published in The Lancet Sub-Journal

On November 14, a research team led by Prof. Kan Gong and Associate Chief Physician Yi Liu from the Department of Urology, Peking University First Hospital and the Institute of Urology, Peking University, published a major advancement in precision prostate biopsy in eClinicalMedicine, a sub-journal of The Lancet.
Professor Ning-NingLu: Precision Radiotherapy in Urologic Malignancies: State-of-the-Art Clinical Practices and Emerging Strategies

Professor Ning-NingLu: Precision Radiotherapy in Urologic Malignancies: State-of-the-Art Clinical Practices and Emerging Strategies

With China’s population undergoing demographic aging and growing public awareness of cancer screening, the clinical need for the management of urologic malignancies is steadily increasing. Radiotherapy, a mainstay of oncologic treatment, has evolved rapidly—progressing from old techniques to intensity‑modulated radiotherapy (IMRT), and from conventional fractionation regimens to stereotactic body radiation therapy (SBRT). Precision radiotherapy is now emerging as a pivotal modality in the management of urologic cancers. Professor Ningning Lu, affiliated to the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, has dedicated years to the field of precision radiotherapy for urologic tumors, amassing substantial clinical expertise and a robust research portfolio. UroStream invited Professor Lu to deliver an in-depth review of the clinical applications of precision radiotherapy in urologic malignancies, thereby providing evidence-based insights and practical guidance for clinicians.
Lerociclib and Entinostat Regimens Now Cover the Full Treatment Spectrum of HR+/HER2− Advanced Breast Cancer: Inclusion in the New National Reimbursement List Enhances Access to “Effective, Safe, and Convenient” Therapies

Lerociclib and Entinostat Regimens Now Cover the Full Treatment Spectrum of HR+/HER2− Advanced Breast Cancer: Inclusion in the New National Reimbursement List Enhances Access to “Effective, Safe, and Convenient” Therapies

Hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) breast cancer accounts for approximately 70% of all breast cancer cases. Treatment for this subtype has entered the era of precision “endocrine plus” therapy. Endocrine therapy combined with CDK4/6 inhibitors has become the standard first-line treatment for advanced disease; however, differences in efficacy and safety exist among available agents.